Sector News

Pronutria announces $42.5 million investment from Nestlé Health Science

February 24, 2016
Life sciences

Pronutria Biosciences Inc., a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, announced today that it has completed a $42.5 million investment by Nestlé Health Science.

The proceeds from this financing will help to fund the ongoing rapid transformation of the company from a unique and revolutionary platform to late stage clinical candidates in several disease indications.

“We are delighted with the support from Nestlé Health Science and recognition of the rapid progress we have made towards the clinic with several lead candidates,” said Robert Connelly, President and CEO of Pronutria. “We intend to demonstrate the breadth of our technology by expanding the existing muscle, neurological and liver disease programs.”

“We are forging an innovation frontier for nutritional therapy in healthcare and the paradigm-changing science at Pronutria is a perfect fit for our goals of improving patient health with new approaches that have broad application,” said Greg Behar, Nestlé Health Science CEO. Alongside the investment he will join the Pronutria board of directors.

“Our experience with Nestlé Health Science is that they are an excellent and committed partner with an innovative vision of the future of patient care,” said Dr. Noubar Afeyan, CEO of Flagship Ventures, and co-founder and Chairman of Pronutria. “We look forward to working closely with them to expand this relationship for generating meaningful patient and economic value.”

Source: Pronutria

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.